Paper Details

  1. Home
  2. Paper Details

A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil.

Author: BurtTal, DyskenMaurice, FinkelSanford I, KrishnanK R R, McRaeThomas, MintzerJacobo E

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Sertraline augmentation therapy was well-tolerated in Alzheimer's disease patients treated with donepezil. While there was no overall significant difference in efficacy compared to placebo, post hoc analyses showed modest improvement with sertraline in some patients.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To examine the safety and efficacy of sertraline augmentation therapy in the treatment of behavioral manifestations of Alzheimer's disease (AD) in outpatients treated with donepezil. METHODS AND MATERIALS: Patients with probable or possible AD, and a Neuropsychiatric Inventory (NPI) tota...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/gps.998

データ提供：米国国立医学図書館（NLM）

Sertraline Augmentation: A Promising Approach for Alzheimer's Disease?

[Alzheimer's disease (AD)] is a devastating neurological condition characterized by [cognitive decline and behavioral disturbances]. This study investigates the potential of [sertraline augmentation therapy] to improve the [behavioral symptoms of AD] in patients already taking [donepezil], a medication for [AD]. The authors used [a randomized, placebo-controlled trial] to compare the effectiveness of [sertraline augmentation] with [placebo augmentation] in [AD patients]. While the results were not statistically significant overall, a [subgroup analysis] revealed that [patients with moderate-to-severe behavioral symptoms] showed a significant improvement in their [NPI-behavioral subscale scores] with [sertraline augmentation]. This finding suggests that [sertraline augmentation] may be a promising approach for [managing behavioral disturbances in AD].

Sertraline: A Potential Solution for Behavioral Disturbances in Alzheimer's Disease

The study found that [sertraline augmentation] may offer some benefit for [patients with moderate-to-severe behavioral symptoms of AD]. It’s like a camel finding a hidden oasis in a harsh desert – a surprise discovery that could provide [relief and support] for those struggling with [the challenges of AD].

A New Direction in Alzheimer's Treatment

This research suggests that [sertraline augmentation] may be a valuable tool for [managing behavioral disturbances in AD]. It’s a reminder that [research is constantly evolving], and [new therapies are being developed] all the time. The findings suggest that [sertraline augmentation] could offer a new direction for [treating the behavioral aspects of AD].

Dr.Camel's Conclusion

This study suggests that [sertraline augmentation] may be a promising approach for [managing behavioral disturbances in AD]. While further research is needed, the findings offer a glimmer of hope for [patients struggling with the challenges of AD].

Date :
  1. Date Completed 2004-04-01
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

14716694

DOI: Digital Object Identifier

10.1002/gps.998

Related Literature

Article Analysis
・Effective treatment of alzheimer's disease
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.